About Michael Byrnes
Michael Byrnes is a chief financial officer at FORE US Bio.
Michael Byrnes reports to the SEC as a director or officer of 3 public companies: Cero Therapeutics (CERO), eFFECTOR Therapeutics (EFTR) and Ocera Therapeutics (OCRX).
Michael Byrnes first appears on SEC filings in 2014.
Experience
This experience comes from Michael Byrnes's profile and from SEC filings. For roles taken from filings, the years are when the filings name Michael Byrnes in the role, so the role may have started earlier or lasted longer.
FORE US Bio Inc. Current
Chief Financial Officer
2024 – Present · Philadelphia, PA
Develops targeted cancer drugs for patients whose tumors have specific genetic changes.
CI
Cero Therapeutics Holdings, Inc. Current
Member Board of Directors
2024 – Present · Public company (CERO)
EI
eFFECTOR Therapeutics, Inc.
Chief Financial Officer
2020 – 2024 · Public company (EFTR)
PB
Principia Biopharma
Sr. Vice President, Finance
2020
AI
Alkahest, Inc.
Chief Financial Officer
2018 – 2020
OI
Ocera Therapeutics, Inc.
CFO and Treasurer
Chief Financial Officer (2014 – 2017)
2014 – 2017 · Public company (OCRX)
MA
Maxygen
Corporate Controller
2010 – 2014
NI
NeurogesX, Inc.
Director, Finance
2007 – 2010
LS
Lipid Sciences
Manager, Finance & Accounting
2002 – 2007
AC
ADAC Laboratories, A Philips Medical Systems Company
Financial Analyst
2000 – 2002
BC
Bay View Capital
GL Accountant
1997 – 2000
Key Colleagues at Startups
The people Michael Byrnes works with at each company, as listed on that company's latest Form D.
FORE US Bio Inc. · Form D/A, Jul 14, 2026
William Hinshaw
Executive officer and director
Giovanni Mariggi
Co-founder and Partner at Medicxi, director
Kim Blackwell
Director
Erez Chimovits
Senior Managing Director at Orbimed
RD
Rajeev Dadoo
COO and Managing Partner of SR One, director
Dieter Weinand
Chairman of the Board
Chandra Leo
Partner at HBM Partners and director